Aligos Therapeutics, Inc. (ALGS) intrinsic value & 10-year financials
Aligos Therapeutics, Inc. (ALGS) has a Graham intrinsic value of $153.58 per share. At $4.86 on Oct 17, 2026, the stock trades 97% below that value. Over the last 8 fiscal years revenue shrank 40.6% a year to $2.2M, with an average return on invested capital of 579.9%.
- Graham intrinsic value
- $153.58
- Share price (Oct 17, 2026)
- $4.86
- Price vs Graham value
- 97% below
- Market cap
- $48.0M
- Revenue (FY2025)
- $2.2M
- Revenue growth (8-yr CAGR)
- -40.6%
- ROIC (10-yr avg)
- 579.9%
- Free cash flow (FY2025)
- —
ALGS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $2.2M | -$24.2M | -$2.45 | — | -4024.9% | 724.6% |
| FY2024 | $3.6M | -$131.2M | -$20.94 | -$80.9M | -2469.0% | 184.2% |
| FY2023 | $6.2M | -$87.7M | -$1.36 | -$79.0M | -1423.5% | 4711.4% |
| FY2022 | $0 | -$96.0M | -$2.25 | -$80.3M | — | -470.9% |
| FY2021 | $0 | -$128.3M | — | -$116.6M | — | -1308.1% |
| FY2020 | $0 | -$108.5M | — | -$76.3M | — | 174.1% |
| FY2019 | — | -$52.3M | — | -$49.6M | — | 44.1% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Aligos Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Aligos Therapeutics, Inc. returns on capital have been average, hovering around 12.0% ROIC over the decade.
Aligos Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Aligos Therapeutics, Inc. is modeled at -40.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $153.58 per share.